

- ***What proportion of new cancer drugs extend survival or improve quality of life?***
- 68 cancer indications approved by the European Medicines Agency 2009-2013



- Most new cancer drugs (57%) approved without evidence they extend survival or improve quality of life
- After median 5 years on the market, only an additional 8 drug indications showed survival/QoL gains
- Of 68 cancer indications approved by the EMA, and with a median 5 years follow-up, only 35 (51%) had shown survival/QoL gain over existing treatments or placebo

- Of 23 drugs with a survival benefit, less than half (48%) were judged to offer a clinically meaningful benefit
- For the remaining 33/68 (49%), uncertainty remains over whether the drugs extend survival or improve quality of life.